Strategic Leader in Drug Discovery, R&D, Global Operational Excellence and Business Strategy

AREAS OF EXPERTISE

Medicinal Chemistry

Product Innovation

Drug Desicovery & Development

Research & Development

Healthcare

Global Outsourcing

Operational Excellence

Clinical Reserach & Development

Global Pharmaceutical Strategies

Contract/Generic Manufacturing

EXPERIENCE

xCell Strategic Consulting – Principal

Pharma Innovation Sourcing Center -  Founder and CEO

Scientific Advisory Board, Sri Ramachandra Medical University

Advisor, venBIO

Board Member, Oncobiologics

Board of Directors, Parilis Biopharma

Advisory Board Member, Zydus Cadila Pharma

Scientific Advisory Board, Pharmaceutical Strategy Series, Cambridge Health Institute

BMS-Biocon R&D Center– Managing Director

Bristol-Myers Squibb  – Research & Development

ASSOCIATIONS

Pharma Innovation Sourcing Center - Founder and CEO 

Scientfic Advisory Board, Sri Ramachandra Medical University

EDUCATION

PhD, Wayne University


 

 

 

Balu N. Balasubramanian, Ph.D, Principal

Dr. Balasubramanian brings more than 26 years of extensive life sciences and strategic leadership experience in the areas of drug discovery, R&D, global operational excellence and business strategy management. His experience includes large, global biopharmaceutical manufacturing, clinical research and development and generic and contact manufacturing..

Highlights:

  • Established academic-industry partnership programs in India to increase drug discovery awareness and local talent
     
  • Conceived and built the Bristol-Myers Squibb-Biocon R&D Center (BBRC) located in India; exemplifying affordable innovation, operational excellence in drug discovery and early clinical development
    • Under his leadership, expanded capabilities as an integrated research and early clinical development center with over 450 scientists, from hit to lead to Phase ll clinical studies
       
    • Delivered fourteen clinical candidates
       
  • Led programs in cardiovascular, metabolic diseases, oncology, immunology, infectious diseases and neuroscience; ultimately identifying eleven clinical candidates
     
  • Authored/Co-authored more than seventy-five scientific publications, patents and presentations